



FOR IMMEDIATE RELEASE

Guardion Health Sciences, Inc.
15150 Avenue of Science, Ste. 200
San Diego, CA 92128
Ph 858.605.9055; Fax 858.630.5543
www.guardionhealth.com

**Guardion Health Sciences receives patent
for its diagnostic device, the MapcatSF**

San Diego, California – Nov 10, 2016 – Guardion Health Sciences is pleased to announce that the patent for its MapcatSF® diagnostic device has been issued by the United States Patent and Trademark Office.

The MapcatSF® is GHS's premier cutting-edge diagnostic device for measuring the density of the macular protective pigment, providing eye care professionals the ability to accurately measure and monitor levels of the critical macular carotenoids. The MapcatSF®, together with Lumega-Z®, the company's unique medical food, provides an evidence-based protocol to manage the condition of a depleted macular pigment. Macular pigment is a known biomarker for overall retinal health, and a modifiable risk factor against retinal disease.

About Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods with an initial medical food product that addresses a depleted macular protective pigment, which is a known risk factor for causing age-related macular degeneration (“AMD”), as well as computer vision syndrome (“CVS”). Guardion Health Sciences, Inc. has also developed a proprietary medical device that accurately measures the macular pigment density.

Guardion Health Sciences, Inc. currently develops and distributes a line of medical foods that restores the macular protective pigment to address AMD and CVS under the brand name Lumega-Z®. Guardion Health Sciences, Inc. is using its own proprietary patented

technology embodied in a medical device called the MapcatSF® that measures the macular pigment. The MapcatSF® is a patented (patent number: US9486136), non-mydratic, non-invasive medical device that accurately measures the macular protective pigment density, thereby creating an evidence-based protocol that is shared with the patient

###